<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Meiragtx Holdings Plc — News on 6ix</title>
    <link>https://6ix.com/company/meiragtx-holdings-plc</link>
    <description>Latest news and press releases for Meiragtx Holdings Plc on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Thu, 16 Apr 2026 04:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/meiragtx-holdings-plc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683598e878dffbe2df105a06.webp</url>
      <title>Meiragtx Holdings Plc</title>
      <link>https://6ix.com/company/meiragtx-holdings-plc</link>
    </image>
    <item>
      <title>MeiraGTx Announces Pricing of $100 Million Offering of Ordinary Shares</title>
      <link>https://6ix.com/company/meiragtx-holdings-plc/news/meiragtx-announces-pricing-of-dollar100-million-offering-of-ordinary-shares</link>
      <guid isPermaLink="true">https://6ix.com/company/meiragtx-holdings-plc/news/meiragtx-announces-pricing-of-dollar100-million-offering-of-ordinary-shares</guid>
      <pubDate>Thu, 16 Apr 2026 04:00:00 GMT</pubDate>
      <description>LONDON and NEW YORK, April 16, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines</description>
    </item>
    <item>
      <title>MeiraGTx Announces Positive Three-year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Late Radiation-Induced Xerostomia</title>
      <link>https://6ix.com/company/meiragtx-holdings-plc/news/meiragtx-announces-positive-three-year-data-from-the-phase-1-aquax-clinical-study-of-aav-haqp1-for-the-treatment-of-grade-23-late-radiation-induced-xerostomia</link>
      <guid isPermaLink="true">https://6ix.com/company/meiragtx-holdings-plc/news/meiragtx-announces-positive-three-year-data-from-the-phase-1-aquax-clinical-study-of-aav-haqp1-for-the-treatment-of-grade-23-late-radiation-induced-xerostomia</guid>
      <pubDate>Thu, 16 Apr 2026 04:00:00 GMT</pubDate>
      <description>Clinically meaningful improvements in xerostomia symptoms measured by PRO Xerostomia Questionnaire (XQ) maintained out to 3 years post treatment with</description>
    </item>
    <item>
      <title>MeiraGTx to Present 3-Year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Thursday, April 16, 2026</title>
      <link>https://6ix.com/company/meiragtx-holdings-plc/news/meiragtx-to-present-3-year-data-from-the-phase-1-aquax-clinical-study-of-aav-haqp1-for-the-treatment-of-grade-23-radiation-induced-xerostomia-on-thursday-april-16-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/meiragtx-holdings-plc/news/meiragtx-to-present-3-year-data-from-the-phase-1-aquax-clinical-study-of-aav-haqp1-for-the-treatment-of-grade-23-radiation-induced-xerostomia-on-thursday-april-16-2026</guid>
      <pubDate>Tue, 14 Apr 2026 12:30:00 GMT</pubDate>
      <description>- Presentation to include 3-year data from all cohorts of the Phase 1 AQUAx Clinical Study - Cohort-level data and individual patient data from bilateral and unilateral cohorts will be presented for both PRO and objective measures. LONDON and NEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced it will host a conference call and webcast to present 3-year data from the long-term follow</description>
    </item>
    <item>
      <title>MeiraGTx Announces FDA Breakthrough Therapy Designation for AAV2-hAQP1 for the Treatment of Grade 2 and Grade 3 Radiation-Induced Xerostomia (RIX) and Reports Fourth Quarter and Full Year 2025 Financial and Operational Results</title>
      <link>https://6ix.com/company/meiragtx-holdings-plc/news/meiragtx-announces-fda-breakthrough-therapy-designation-for-aav2-haqp1-for-the-treatment-of-grade-2-and-grade-3-radiation-induced-xerostomia-rix-and-reports-fourth-quarter-and-full-year-2025-financial-and-operational-results</link>
      <guid isPermaLink="true">https://6ix.com/company/meiragtx-holdings-plc/news/meiragtx-announces-fda-breakthrough-therapy-designation-for-aav2-haqp1-for-the-treatment-of-grade-2-and-grade-3-radiation-induced-xerostomia-rix-and-reports-fourth-quarter-and-full-year-2025-financial-and-operational-results</guid>
      <pubDate>Thu, 26 Mar 2026 04:00:00 GMT</pubDate>
      <description>FDA granted Breakthrough Therapy Designation for AAV2-hAQP1 for the treatment of Grade 2 and Grade 3 late xerostomia caused by radiotherapy for cancers of the</description>
    </item>
    <item>
      <title>ZipBio and MeiraGTx Enter into Exclusive License Agreement to Advance First-in-Class AAV Gene Therapy for Geographic Atrophy</title>
      <link>https://6ix.com/company/meiragtx-holdings-plc/news/zipbio-and-meiragtx-enter-exclusive-license-agreement-advance-first-class-aav-gene</link>
      <guid isPermaLink="true">https://6ix.com/company/meiragtx-holdings-plc/news/zipbio-and-meiragtx-enter-exclusive-license-agreement-advance-first-class-aav-gene</guid>
      <pubDate>Tue, 03 Feb 2026 05:00:00 GMT</pubDate>
      <description>BOSTON, Feb. 3, 2026 /PRNewswire/ -- ZipBio, a biotechnology company pioneering AI-driven protein therapeutics, announced an exclusive license agreement with</description>
    </item>
    <item>
      <title>MeiraGTx Reports Third Quarter 2025 Financial and Operational Results</title>
      <link>https://6ix.com/company/meiragtx-holdings-plc/news/meiragtx-reports-third-quarter-2025-financial-and-operational-results-2025-11-13</link>
      <guid isPermaLink="true">https://6ix.com/company/meiragtx-holdings-plc/news/meiragtx-reports-third-quarter-2025-financial-and-operational-results-2025-11-13</guid>
      <pubDate>Thu, 13 Nov 2025 05:00:00 GMT</pubDate>
      <description>Entered into broad strategic collaboration with Eli Lilly and Company (“Lilly”) in the area of ophthalmology, granting Lilly worldwide exclusive rights to</description>
    </item>
    <item>
      <title>MeiraGTx Enters into Strategic Collaboration with Eli Lilly and Company to Develop and Commercialize Genetic Medicines in Ophthalmology</title>
      <link>https://6ix.com/company/meiragtx-holdings-plc/news/meiragtx-enters-strategic-collaboration-eli-lilly-and-company-develop-and</link>
      <guid isPermaLink="true">https://6ix.com/company/meiragtx-holdings-plc/news/meiragtx-enters-strategic-collaboration-eli-lilly-and-company-develop-and</guid>
      <pubDate>Mon, 10 Nov 2025 05:00:00 GMT</pubDate>
      <description>LONDON and NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines</description>
    </item>
    <item>
      <title>MeiraGTx Announces Two Posters at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress</title>
      <link>https://6ix.com/company/meiragtx-holdings-plc/news/meiragtx-announces-two-posters-european-society-gene-and-cell-therapy-esgct-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/meiragtx-holdings-plc/news/meiragtx-announces-two-posters-european-society-gene-and-cell-therapy-esgct-2025</guid>
      <pubDate>Tue, 07 Oct 2025 04:00:00 GMT</pubDate>
      <description>Multiple Posters Highlight the Breadth of Company’s Novel Genetic Medicine and Cell Therapy Platforms LONDON and NEW YORK, Oct. 07, 2025 (GLOBE NEWSWIRE) --</description>
    </item>
    <item>
      <title>MeiraGTx Reports Second Quarter 2025 Financial and Operational Results</title>
      <link>https://6ix.com/company/meiragtx-holdings-plc/news/meiragtx-reports-second-quarter-2025-financial-and-operational-results-2025-08-14</link>
      <guid isPermaLink="true">https://6ix.com/company/meiragtx-holdings-plc/news/meiragtx-reports-second-quarter-2025-financial-and-operational-results-2025-08-14</guid>
      <pubDate>Thu, 14 Aug 2025 04:00:00 GMT</pubDate>
      <description>- Gained alignment with U.S. Food and Drug Administration (FDA) on the ongoing Phase 2 AQUAx2 randomized double-blind, placebo-controlled pivotal study in</description>
    </item>
    <item>
      <title>MeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting</title>
      <link>https://6ix.com/company/meiragtx-holdings-plc/news/meiragtx-announces-presentation-four-posters-american-society-gene-and-cell-therapy</link>
      <guid isPermaLink="true">https://6ix.com/company/meiragtx-holdings-plc/news/meiragtx-announces-presentation-four-posters-american-society-gene-and-cell-therapy</guid>
      <pubDate>Tue, 13 May 2025 04:00:00 GMT</pubDate>
      <description>Multiple Poster Presentations Highlight the Depth and Novelty of MeiraGTx’s Technology Platforms for Gene and Cell Therapy LONDON and NEW YORK, May 13, 2025</description>
    </item>
    <item>
      <title>MeiraGTx Reports First Quarter 2025 Financial and Operational Results</title>
      <link>https://6ix.com/company/meiragtx-holdings-plc/news/meiragtx-reports-first-quarter-2025-financial-and-operational-results-2025-05-13</link>
      <guid isPermaLink="true">https://6ix.com/company/meiragtx-holdings-plc/news/meiragtx-reports-first-quarter-2025-financial-and-operational-results-2025-05-13</guid>
      <pubDate>Tue, 13 May 2025 04:00:00 GMT</pubDate>
      <description>- Announced strategic collaboration with Hologen AI, including a $200 million cash upfront payment to MeiraGTx and the formation of a joint venture, Hologen</description>
    </item>
    <item>
      <title>MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson’s Disease</title>
      <link>https://6ix.com/company/meiragtx-holdings-plc/news/meiragtx-granted-fda-regenerative-medicine-advanced-therapy-rmat-designation-aav-gad</link>
      <guid isPermaLink="true">https://6ix.com/company/meiragtx-holdings-plc/news/meiragtx-granted-fda-regenerative-medicine-advanced-therapy-rmat-designation-aav-gad</guid>
      <pubDate>Fri, 09 May 2025 04:00:00 GMT</pubDate>
      <description>- This RMAT designation is based on data from 3 clinical studies demonstrating the potential benefit of AAV-GAD as a one-time treatment for Parkinson’s</description>
    </item>
    <item>
      <title>MeiraGTx Reports Fourth Quarter and Full Year 2024 Financial and Operational Results and Recent Business Updates</title>
      <link>https://6ix.com/company/meiragtx-holdings-plc/news/meiragtx-reports-fourth-quarter-and-full-year-2024-financial-and-operational-results</link>
      <guid isPermaLink="true">https://6ix.com/company/meiragtx-holdings-plc/news/meiragtx-reports-fourth-quarter-and-full-year-2024-financial-and-operational-results</guid>
      <pubDate>Thu, 13 Mar 2025 04:00:00 GMT</pubDate>
      <description>- Today announced strategic collaboration with Hologen AI, including a $200 million upfront payment to MeiraGTx and the formation of a joint venture, Hologen</description>
    </item>
    <item>
      <title>MeiraGTx Enters into a Strategic Collaboration with Hologen AI to Expedite Phase 3 Development of AAV-GAD for Parkinson’s Disease and Industrialize MeiraGTx’s Proprietary Manufacturing Process</title>
      <link>https://6ix.com/company/meiragtx-holdings-plc/news/meiragtx-enters-strategic-collaboration-hologen-ai-expedite-phase-3-development-aav</link>
      <guid isPermaLink="true">https://6ix.com/company/meiragtx-holdings-plc/news/meiragtx-enters-strategic-collaboration-hologen-ai-expedite-phase-3-development-aav</guid>
      <pubDate>Thu, 13 Mar 2025 04:00:00 GMT</pubDate>
      <description>- MeiraGTx to receive $200 million in upfront cash consideration - MeiraGTx and Hologen will form a joint venture, Hologen Neuro AI Ltd, with an additional</description>
    </item>
    <item>
      <title>MeiraGTx Announces The Lancet Publication of Data Demonstrating the Efficacy of rAAV8.hRKp.AIPL1 for the Treatment of Leber Congenital Amaurosis 4 (LCA4) Retinal Dystrophy</title>
      <link>https://6ix.com/company/meiragtx-holdings-plc/news/meiragtx-announces-lancet-publication-data-demonstrating-efficacy-raav8hrkpaipl1</link>
      <guid isPermaLink="true">https://6ix.com/company/meiragtx-holdings-plc/news/meiragtx-announces-lancet-publication-data-demonstrating-efficacy-raav8hrkpaipl1</guid>
      <pubDate>Fri, 21 Feb 2025 05:00:00 GMT</pubDate>
      <description>As disclosed in the paper, 4 out of 4 young children with the AIPL1-related retinal dystrophy, LCA4, benefited substantially from unilateral subretinal</description>
    </item>
    <item>
      <title>MeiraGTx Receives Rare Pediatric Disease Designation from FDA for AAV8-RK-RetGC for the Treatment of Patients with Leber Congenital Amaurosis due to GUCY2D Mutations</title>
      <link>https://6ix.com/company/meiragtx-holdings-plc/news/meiragtx-receives-rare-pediatric-disease-designation-fda-aav8-rk-retgc-treatment</link>
      <guid isPermaLink="true">https://6ix.com/company/meiragtx-holdings-plc/news/meiragtx-receives-rare-pediatric-disease-designation-fda-aav8-rk-retgc-treatment</guid>
      <pubDate>Wed, 22 Jan 2025 05:00:00 GMT</pubDate>
      <description>MeiraGTx has recently received Rare Pediatric Disease Designation (RPDD) for four inherited retinal diseases (IRDs) reflecting the transformative therapeutic</description>
    </item>
    <item>
      <title>MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia</title>
      <link>https://6ix.com/company/meiragtx-holdings-plc/news/meiragtx-granted-fda-regenerative-medicine-advanced-therapy-rmat-designation-aav2</link>
      <guid isPermaLink="true">https://6ix.com/company/meiragtx-holdings-plc/news/meiragtx-granted-fda-regenerative-medicine-advanced-therapy-rmat-designation-aav2</guid>
      <pubDate>Mon, 09 Dec 2024 05:00:00 GMT</pubDate>
      <description>- RMAT designation recognizes the preliminary clinical evidence of the potential benefit of AAV2-hAQP1 as a one-time treatment for this debilitating condition</description>
    </item>
    <item>
      <title>Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors</title>
      <link>https://6ix.com/company/meiragtx-holdings-plc/news/ascentage-pharma-appoints-ms-marina-s-bozilenko-and-dr-debra-yu-independent-non</link>
      <guid isPermaLink="true">https://6ix.com/company/meiragtx-holdings-plc/news/ascentage-pharma-appoints-ms-marina-s-bozilenko-and-dr-debra-yu-independent-non</guid>
      <pubDate>Sun, 24 Nov 2024 05:00:00 GMT</pubDate>
      <description>ROCKVILLE, Md. and SUZHOU, China, Nov. 24, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering,</description>
    </item>
    <item>
      <title>MeiraGTx Announces Third Quarter 2024 Financial and Operational Results and Recent Business Updates</title>
      <link>https://6ix.com/company/meiragtx-holdings-plc/news/meiragtx-announces-third-quarter-2024-financial-and-operational-results-and-recent</link>
      <guid isPermaLink="true">https://6ix.com/company/meiragtx-holdings-plc/news/meiragtx-announces-third-quarter-2024-financial-and-operational-results-and-recent</guid>
      <pubDate>Wed, 13 Nov 2024 05:00:00 GMT</pubDate>
      <description>Received 3 Rare Pediatric Disease Designations (RPDD) from FDA for each of 3 potential therapies for 3 different rare inherited retinopathies including</description>
    </item>
    <item>
      <title>MeiraGTx Announces Five Posters at the European Society of Gene and Cell Therapy (ESGCT) 2024 Annual Congress</title>
      <link>https://6ix.com/company/meiragtx-holdings-plc/news/meiragtx-announces-five-posters-european-society-gene-and-cell-therapy-esgct-2024</link>
      <guid isPermaLink="true">https://6ix.com/company/meiragtx-holdings-plc/news/meiragtx-announces-five-posters-european-society-gene-and-cell-therapy-esgct-2024</guid>
      <pubDate>Tue, 22 Oct 2024 04:00:00 GMT</pubDate>
      <description>Multiple Posters Highlight the Breadth of Company’s Novel Genetic Medicine and Cell Therapy Platforms LONDON and NEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) --</description>
    </item>
  </channel>
</rss>